A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03849469 |
|
Recruitment Status :
Completed
First Posted : February 21, 2019
Last Update Posted : March 30, 2023
|
Sponsor:
Xencor, Inc.
Collaborator:
ICON Clinical Research
Information provided by (Responsible Party):
Xencor, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess safety, tolerability, pharmacokinetics, immunogenicity, and anti-tumor activity of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with select advanced solid tumors.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Melanoma Cervical Carcinoma Pancreatic Carcinoma Triple Negative Breast Cancer Hepatocellular Carcinoma Urothelial Carcinoma Squamous Cell Carcinoma of the Head and Neck Nasopharyngeal Carcinoma Renal Cell Carcinoma Non-small Cell Lung Carcinoma Small Cell Lung Carcinoma Gastric or Gastroesophageal Junction Adenocarcinoma Advanced or Metastatic Solid Tumors Prostate Carcinoma Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma Intrahepatic Cholangiocarcinoma Squamous Cell Anal Cancer Squamous Cell Penile Carcinoma Squamous Cell Vulvar Carcinoma Colorectal Carcinoma Endometrial Carcinoma | Biological: XmAb®22841 Biological: Pembrolizumab (Keytruda®) | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 78 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4) |
| Actual Study Start Date : | May 29, 2019 |
| Actual Primary Completion Date : | February 16, 2023 |
| Actual Study Completion Date : | February 16, 2023 |
Resource links provided by the National Library of Medicine
Drug Information
available for:
Pembrolizumab
Genetic and Rare Diseases Information Center resources:
Stomach Cancer
Pancreatic Cancer
Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Ovarian Cancer
Ovarian Epithelial Cancer
Nasopharyngeal Carcinoma
Small Cell Lung Cancer
Bile Duct Cancer
Intrahepatic Cholangiocarcinoma
Anal Cancer
Transitional Cell Carcinoma
Penile Cancer
Fallopian Tube Cancer
Vulvar Cancer
Neuroendocrine Tumor
Neuroepithelioma
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Arm 1
Arm 1: XmAb®22841 Monotherapy
|
Biological: XmAb®22841
Monoclonal bispecific antibody |
|
Experimental: Arm 2
Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®)
|
Biological: XmAb®22841
Monoclonal bispecific antibody Biological: Pembrolizumab (Keytruda®) FDA-approved humanized monoclonal antibody |
Primary Outcome Measures :
- Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03. [ Time Frame: 56 Days ]Rates of treatment-related adverse events (AEs), graded by CTCAE v4.03, and additionally categorized as either immune-related or non-immune AEs.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
PART A (Dose Escalation Cohorts)
- All subjects' cancer must have progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment.
- All subjects must have adequate archival tumor, or give consent to a fresh tumor biopsy.
- Subjects have an ECOG performance status of 0-1.
-
Subjects in monotherapy and combination therapy cohorts must have histologically or cytologically confirmed advanced or metastatic solid tumors, including the following:
- Melanoma
- Cervical carcinoma
- Pancreatic carcinoma
- Breast carcinoma that is estrogen receptor, progesterone receptor, and Her2 negative (TNBC)
- Hepatocellular carcinoma
- Urothelial carcinoma
- Squamous cell carcinoma of the head and neck (HNSCC)
- Nasopharyngeal carcinoma (NPC)
- Renal cell carcinoma
- Colorectal carcinoma or endometrial carcinoma
- Small cell lung carcinoma or NSCLC
- Gastric or gastroesophageal junction adenocarcinoma
- Prostate adenocarcinoma
- Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
- Intrahepatic cholangiocarcinoma
-
Subjects in the combination cohorts in Part A with XmAb22841 and pembrolizumab may have an advanced solid tumor that either:
- has progressed after treatment with all available therapies that are known to confer clinical benefit, or is intolerant or has refused standard treatment (as for the XmAb22841 monotherapy cohorts), or
- is of a tumor type for which pembrolizumab is an approved indication and has not previously been treated with an agent targeting PD1 or PDL1.
PART B (Dose Expansion Cohorts)
XmAb22841 Single Agent Cohort
1. Must have histologically or cytologically confirmed advanced or metastatic solid tumor that has progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. Eligible tumor types include the following:
- Anti-PD1 refractory melanoma (or any uveal melanoma)
- Anti-PD1 refractory NSCLC
- Anti-PD1 refractory renal cell carcinoma (with clear cell component)
- Anti-PD1 refractory urothelial carcinoma
- Head and neck squamous cell carcinoma
- Hepatocellular carcinoma
- Gastric adenocarcinoma
- Cervical carcinoma
- Breast carcinoma that is estrogen receptor, progesterone receptor, and HER2 negative (TNBC)
- Epithelial ovarian cancer
- Nasopharyngeal carcinoma
- Squamous cell anal carcinoma
- Squamous cell penile carcinoma
- Squamous cell vulvar carcinoma
XmAb22841 + Pembrolizumab Cohorts
- Anti-PD-1 refractory melanoma (excluding uveal melanoma)
- Anti-PD-1 naïve melanoma (excluding uveal melanoma)
- Anti-PD-1 refractory NSCLC
-
Anti-PD1 naïve NSCLC
a. Must be PD-L1 high (TPS ≥ 50%), with no EGFR or ALK aberrations
-
Anti-PD1 naïve urothelial carcinoma
- Must be PDL1 positive (CPS of ≥ 10), or ineligible for any platinum-containing chemotherapy regardless of PDL1 status; or
- Had disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
Exclusion Criteria:
- Prior treatment with an investigational anti-LAG3 therapy.
- Treatment with any CTLA4 antibody within 16 weeks of the start of study drug for Cohorts 1M, 2M, 3M, 1P, and 2P; within 8 weeks for Cohorts 4M, 5M, 3P, 4P and 4Pi; and within 3 weeks for Cohorts 6M, 7Mi, 7M, 5P, and 6P.
- Systemic antineoplastic therapy, unconjugated antibody therapy within 4 weeks of the first dose of study treatment; or radiotherapy within 2 weeks of the first dose of study treatment; or small molecule kinase inhibitors within 6 elimination half-lives of the first dose of study treatment.
- Have received prior therapy with an anti-PD1, anti-PDL1, or anti PDL2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA4, OX 40, CD137) AND were permanently discontinued from that treatment due to an irAE.
- Failure to recover from any irAE from prior cancer therapy to Grade ≤ 1.
- Failure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to Grade ≤ 2.
- Active known or suspected autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus; residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and non-steroidal anti-inflammatory drugs).
- Receipt of an organ allograft.
- Treatment with antibiotics within 14 days prior to first dose of study drug.
- Participants with known HIV.
- Participants with known chronic hepatitis B virus (HBV) infection treated for less than 3 months prior to study enrollment and/or with a detectable HBV viral load; or hepatitis C virus (HCV) infection that has been treated for less than 4 weeks prior to study enrollment and/or with a detectable HCV viral load; or active HBV/HCV coinfection.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03849469
Locations
Show 28 study locations
Sponsors and Collaborators
Xencor, Inc.
ICON Clinical Research
Investigators
| Study Director: | Benjamin Thompson, MD, PhD | Xencor, Inc. |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Xencor, Inc. |
| ClinicalTrials.gov Identifier: | NCT03849469 |
| Other Study ID Numbers: |
XmAb22841-01 DUET-4 ( Other Identifier: Xencor, Inc. ) |
| First Posted: | February 21, 2019 Key Record Dates |
| Last Update Posted: | March 30, 2023 |
| Last Verified: | March 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Xencor, Inc.:
|
DUET-4 Advanced solid tumors Metastatic solid tumors Melanoma Cervical Cancer Pancreatic Cancer Triple Negative Breast Cancer Hepatocellular/Liver Cancer Urothelial Cancer Renal Cell Cancer Squamous Cell Carcinoma of the Head and Neck Non-small Cell Lung Cancer Small Cell Lung Cancer Gastric Cancer |
Gastroesophageal Junction Cancer Lymphocyte-activation gene 3 (LAG3) Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) Prostate Cancer Nasopharyngeal carcinoma Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal carcinoma Intrahepatic cholangiocarcinoma Squamous Cell Anal Carcinoma Squamous Cell Penile Carcinoma Squamous Cell Vulvar Carcinoma Colorectal Carcinoma Endometrial Carcinoma |
Additional relevant MeSH terms:
|
Carcinoma Melanoma Carcinoma, Squamous Cell Ovarian Neoplasms Carcinoma, Ovarian Epithelial Triple Negative Breast Neoplasms Nasopharyngeal Carcinoma Cholangiocarcinoma Fallopian Tube Neoplasms Lung Neoplasms Squamous Cell Carcinoma of Head and Neck Colorectal Neoplasms Endometrial Neoplasms Carcinoma, Non-Small-Cell Lung Anus Neoplasms |
Pancreatic Neoplasms Small Cell Lung Carcinoma Vulvar Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Breast Neoplasms Neoplasms by Site Breast Diseases Skin Diseases Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Nevi and Melanomas |